Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras/MEK/ERK and PI3K/Akt/mTOR pathways
Laura M. Rosenberg(Massachusetts General Hospital), Nancy L. Cho(Brigham and Women's Hospital)
Cited by 48
Related Papers
Sebaceous carcinoma: evidence-based clinical practice guidelines
|The Lancet Oncology|2019|204